Emanuele Crupi: N4 appears to be far more complex than we initially imagined
Emanuele Crupi, Fellow in Medical Oncology at San Raffaele University-Hospital, shared a post on LinkedIn, about a recent paper by him and colleagues, published in JCO Precision Oncology.
“Excited to share the editorial fresh published on JCOPO accompanying our recent study on Nectin4 Positivity in Genitourinary Malignancies.
My congratulations to the authors Zeynep Irem, Ozay Chadi, Hage Chehade, Neeraj Agarwal, Umang Swami.
Special thanks to Niklas Klümper and Markus Eckstein for pioneering contributions that expand our understanding.
N4 appears to be far more complex than we initially imagined:
‘What’ may not be enough. ‘How’ ‘Where’ and ‘When’ are important as well.
Hot topic and provocative questions?
- Is N4 Expression heterogeneity (across stages, histologies) and its dynamic nature (primary vs. metastatic, previous treatment) a result of inconsistent methodologies or a biological reality?
- Conflicting data on N4 expression and response to Enfortumab Vedotin (EV): fact or fairytale?
- N4 amplification: EV-super responder subgroup? What about patients with non-UC N4-amplified malignancies?
- Penile SCC: With its remarkably high N4 expression, could NCT06104618 pave the way for impactful anti-N4 therapies?
A big thanks to JCOPO ASCO for this platform to discuss such an evolving and impactful topic and for allowing us to share our work with the community.”
“Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review”
Authors: Emanuele Crupi, Tiago Costa de Padua, Laura Marandino, Andrea Necchi, Daniele Raggi et al.
More posts featuring Emanuele Crupi.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023